Pacira | PCRX - Current Assets


Pacira reported $562.75M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Assertio Holdings USD 263.57M 53.36M Sep/2025
Astellas Pharma JPY 1.44T 72.43B Dec/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Cara Therapeutics USD 43.13M 4.18M Jun/2025
Coherus Biosciences USD 460.96M 80.75M Sep/2025
Heron Therapeutics USD 229.4M 18.48M Sep/2025
Ironwood Pharmaceuticals USD 273.84M 82.09M Sep/2025
J&J USD 55.62B 1.01B Dec/2025
Ligand Pharmaceuticals USD 753.92M 400.98M Sep/2025
Nektar Therapeutics USD 281.36M 94.79M Sep/2025
Novo Nordisk DKK 172.45B 9.43B Dec/2025
Omeros USD 69.65M 26.53M Jun/2025
Pacira USD 562.75M 182.86M Sep/2025
Perrigo USD 2.88B 264.2M Sep/2025
Pfizer USD 46.92B 3.22B Sep/2025
Supernus Pharmaceuticals USD 593.89M 144.98M Sep/2025
Teva Pharmaceutical Industries USD 13.95B 1.21B Dec/2025
Xeris Pharmaceuticals USD 224.02M 38.44M Sep/2025
Xoma USD 110.71M 5.78M Sep/2025
Zoetis USD 6.77B 185M Dec/2025